Histone deacetylase inhibitors and HIV latency

Current Opinion in HIV and AIDS

Volumn 6, Issue 1, 2011, Pages 25-29

  Margolis, David M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Histone deacetylase inhibitor; HIV; Latency; Resting CD4+ T cells

Indexed keywords

ENFUVIRTIDE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RALTEGRAVIR; VALPROIC ACID; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY T LYMPHOCYTE; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; VIRUS GENE; VIRUS INFECTIVITY; VIRUS LATENCY; DRUG EFFECT; HOST PATHOGEN INTERACTION; METABOLISM; PATHOGENICITY; REVIEW; VIROLOGY;

ANTI-HIV AGENTS; HISTONE DEACETYLASE INHIBITORS; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS LATENCY;

EID: 79954437524     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328341242d     Document Type: Article

References (39)

1. Knezetic JA, Luse DS. The presence of nucleosomes on a DNA template prevents initiation by RNA polymerase II in vitro. Cell 1986; 45:95-104. (Pubitemid 16046630)
2. Courey AJ, Jia S. Transcriptional repression: the long and the short of it. Genes Dev 2001; 15:2786-2796. (Pubitemid 33042049)
3. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074-1080. (Pubitemid 32758077)
4. Kurdistani SK, Grunstein M. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 2003; 4:276-284. (Pubitemid 36383954)
5. Verdin E. DNase l-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type l. J Virol 1991; 65:6790-6799.
6. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22:1868-1877. (Pubitemid 36460143)
7. Bohan C, York D, Srinivasan A. Sodium butyrate activates human immunodeficiency virus long terminal repeat-directed expression. Biochem Biophys Res Commun 1987; 148:899-905. (Pubitemid 18074634)
8. Laughlin MA, Zeichner S, Kolson D, et al. Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology 1993; 196:496-505.
9. Verdin E, Paras P Jr, van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993; 12:3249-3259. (Pubitemid 23232756)
10. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1996; 15:1112-1120. (Pubitemid 26077840)
11. Sheridan PL, Mayall TP, Verdin E, Jones KA. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev 1997; 11:3327-3340. (Pubitemid 28023957)
12. Coull J, Romerio F, Sun J-M, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type-1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000; 74:6790-6799. (Pubitemid 30470662)
13. Williams SA, Chen LF, Kwon H, et al. NFkappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25:139-149. (Pubitemid 43077303)
14. Imai K, Okamoto T. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem 2006; 281:12495-12505. (Pubitemid 43855336)
15. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007; 81:10914-10923. (Pubitemid 47536066)
16. Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J 2007; 26:4985-4995. (Pubitemid 350261291)
17. Marban C, Suzanne S, Dequiedt F, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 2007; 26:412-423. (Pubitemid 46160942)
18. Lusic M, Marcello A, Cereseto A, Giacca M. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J 2003; 22:6550-6561. (Pubitemid 38009602)
19. Keedy KS, Archin NM, Gates AT, et al. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 2009; 83:4749-4756.
20. Archin NM, Keedy KS, Espeseth AS, et al. Expression of latent human immunodeficiency type-1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23:1799-1806.
21. Margolis DM. Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep 2010; 7:37-43.
22. + T cells: can the reservoir of HIV be purged? AIDS 2004; 18:1101-1108.
23. + T-lymphocyte mediated suppression of HIV-1 replication. Virology 2010; 405:234-242.
24. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV infection in vivo. Lancet 2005; 36:549-555.
25. + T cells. AIDS 2008; 22:1131-1135.
26. Sagot-Lerolle N, Lamine A, Chaix ML, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008; 22:1125-1129.
27. Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195:833-836. (Pubitemid 46363928)
28. Archin NM, Espeseth A, Parker D, et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25:207-212.
29. + cell infection. PLoS One 2010; 5:e9390.
30. Contreras X, Schweneker M, Chen CS, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284:6782-6789.
31. Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP. Activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses 2009; 25:883-887.
32. + T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 2010; 54:1-9.
33. Ying H, Zhang Y, Lin S, et al. Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines. Int J Mol Med 2010; 26:265-272.
34. Kauder SE, Bosque A, Lindqvist A, et al. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009; 5:e1000495.
35. Blazkova J, Trejbalova K, Gondois-Rey F, et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009; 5:e1000554.
36. Reuse S, Calao M, Kabeya K, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009; 4:e6093.
37. Savarino A, Mai A, Norelli S, et al. 'Shock and kill' effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009; 6:52.
38. Burnett JC, Lim KI, Calafi A, et al. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010; 84:5958-5974.
39. Perez M, de Vinuesa AG, Sanchez-Duffhues G, et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res 2010; 8:418-429.